A systematic review and meta-analysis of the diagnostic value of circulating microRNA-17-5p in patients with non-small cell lung cancer.

BACKGROUND

nonSmall Cell Lung Cancer (NSCLC) is the most common type of lung cancer with high morbidity and mortality rates. Studies have shown that miR-17-5p levels are significantly increased in the circulating blood of NSCLC patients. This meta-analysis aimed to investigate the diagnostic value of miR-17-5p in NSCLC in China.

METHODS

A literature search was conducted for studies on the correlation between miR-25 and the diagnosis of NSCLC until October 2022 using English and Chinese databases. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) was adopted to evaluate the quality of studies in the literature. Numerical values for sensitivity and specificity were obtained from false negative (FN), false positive (FP), true negative (TN), and true positive (TP) rates, presented alongside graphical representations with boxes marking the values and horizontal lines showing the confidence intervals. Summary Receiver Operating Characteristic (SROC) curves were applied to assess the performance of the diagnostic tests. The data were processed using RevMan 5.3.

RESULTS

Three studies (208 cases of NSCLC patients and 198 healthy controls) met our evaluation criteria. The sensitivity was 0.70 to 0.75, and the specificity value was 0.82 to 0.83. The Area Under the Curve (AUC) from the SROC curves was > 80%; therefore, it was classified as a good category.

CONCLUSION

Our meta-analysis shows that miR-17-5p can be used for the diagnosis of NSCLC and may serve as a biomarker for the detection of early NSCLC in the Chinese population.